ANDA 90424, held by Avet Lifesciences. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 90424 (Ondansetron Hydrochloride), held by Avet Lifesciences, was first approved by FDA on Apr 16, 2010, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 16, 2010 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron HydrochlorideEQ 2MG BASE/ML · injectable;injection | Ondansetron Hydrochloride | Discontinued |
| Apr 19, 2023 | Supplement 19Labeling · Standard review | Approved | None posted |
| Aug 18, 2021 | Supplement 18Labeling · Standard review | Approved | None posted |
| Aug 18, 2021 | Supplement 16Labeling · Standard review | Approved | None posted |
| Jan 15, 2015 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jan 15, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jan 15, 2015 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 15, 2015 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 16, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters